Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03414632 · ClinicalTrials.gov registry record · Early Phase 1
Transthyretin Cardiac Amyloidosis in HFpEF
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 287
- Enrollment target
NCT03414632: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT03414632 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 287 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (442% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03414632, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 287 participants
- Enrollment target
Study Summary
To estimate the prevalence of transthyretin cardiac amyloidosis (TTR-CA) among Heart Failure with Preserved Ejection Fraction (HFpEF) patients with increased LV wall thickness in Southeast Minnesota using 99mTc-PYP single-photon positive emission computed tomography with computed tomography (SPECT/CT).
Primary Outcome
Determine the prevalence of Transthyretin Cardiac Amyloidosis in a community based cohort of consecutive Heart Failure with Preserved Ejection Fraction patients with increased Left Ventricular wall thickness using 99mTc-Pyrophosphate (99mTc-PYP) single-photon positive emission computed tomography with computed tomography (SPECT/CT).
Interventions
- DRUG 99mTc-PYP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2020-03-31 |
| Phase | Early Phase 1 |
What the finished NCT03414632 record still lists
NCT03414632 is an interventional study that assigns participants to a tested intervention. The registered 287 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (442% higher).
The record links to 0 conditions, and to 1 intervention - of which 99mTc-PYP is the first listed.
NCT03414632 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03414632 about?
NCT03414632 is a clinical study titled "Transthyretin Cardiac Amyloidosis in HFpEF". To estimate the prevalence of transthyretin cardiac amyloidosis (TTR-CA) among Heart Failure with Preserved Ejection Fraction (HFpEF) patients with increased LV wall thickness in Southeast Minnesota using 99mTc-PYP single-photon positive emission computed tomography with computed tomography (SPECT/C...
What is the current status of trial NCT03414632?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 287 participants. The study started on 2017-12-01. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT03414632?
The interventions under investigation include: 99mTc-PYP (DRUG).
Who is sponsoring clinical trial NCT03414632?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03414632's enrollment target sits among peer trials
287 39th of 2000 higher than 1,962 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03094429 · 287 participants · Phase 2
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
- NCT06385080 · 287 participants · Phase 1
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- NCT06919224 · 287 participants · NA
Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI